Chat with us
Research Assistance
Online
  • Please enter your first name.

Europe Gastrointestinal Therapeutics Market, 2025-2033

The gastrointestinal therapeutics market in Europe is expected to reach a projected revenue of US$ 14,199.2 million by 2033. A compound annual growth rate of 1.8% is expected of Europe gastrointestinal therapeutics market from 2026 to 2033.

  • Pharmaceuticals
    • GI therapeutics
      • gastrointestinal therapeutics market
Revenue, 2025 (US$M)
$12,319.6
Forecast, 2033 (US$M)
$14,199.2
CAGR, 2026 - 2033
1.8%
Report Coverage
Europe
Europe Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Prism AI by Grand View ResearchFree to try

Ask a question about the gastrointestinal therapeutics market

Every figure cited from GVR research

Europe gastrointestinal therapeutics market highlights

  • The Europe gastrointestinal therapeutics market generated a revenue of USD 12,319.6 million in 2025.
  • The market is expected to grow at a CAGR of 1.8% from 2026 to 2033.
  • In terms of segment, branded was the largest revenue generating drug type in 2025.
  • Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.


Europe data book summary

Market revenue in 2025USD 12,319.6 million
Market revenue in 2033USD 14,199.2 million
Growth rate1.8% (CAGR from 2026 to 2033)
Largest segmentBranded
Fastest growing segmentGenerics
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBranded, Generics
Key market players worldwideAbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares


Other key industry trends

  • In terms of revenue, Europe region accounted for 28.8% of the global gastrointestinal therapeutics market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 14,565.1 million by 2033.

Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.

In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.

Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.

No credit card required*

Publish Date: Mar 20, 2026

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Gastrointestinal Therapeutics Market Companies

NameProfile# EmployeesHQWebsite
Abbott LaboratoriesView profile 114,000100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400www.abbottinvestor.com
AbbVie IncView profile 50,0001 North Waukegan Road, North Chicago, IL, United States, 60064-6400www.abbvieinvestor.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Cipla Ltd DRView profile 38,955Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013www.cipla.com
Bayer AGView profile 99,723Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368www.bayer.com
Sun Pharmaceutical IndustriesView profile 10001+Mumbai, Maharashtra, India, Asiawww.sunpharma.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Gilead Sciences IncView profile 18,000333 Lakeside Drive, Foster, CA, United States, 94404www.gilead.com
Biogen IncView profile 7,570225 Binney Street, Cambridge, MA, United States, 02142www.biogen.com
Takeda Pharmaceutical Co LtdView profile 49,0951-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668www.takeda.com

Europe gastrointestinal therapeutics market

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gastrointestinal Therapeutics Market will help companies and investors design strategic landscapes.


Branded was the largest segment with a revenue share of 68.04% in 2025.

Horizon Databook has segmented the Europe gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.




Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.

In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.

Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.

  • Europe Gastrointestinal Therapeutics Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
    • Branded
    • Generics
  • Europe Gastrointestinal Therapeutics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
    • Aminosalicylates
    • Digestive Enzymes
    • Proton Pump Inhibitors
    • Laxatives
    • Anti-emetics
    • H2 Antagonists
    • Anti-diarrheals
    • Biologics/Biosimilar
    • Other Drug Classes
  • Europe Gastrointestinal Therapeutics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
    • Oral
    • Injectables
    • Others Route of Administrations
  • Europe Gastrointestinal Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Crohn's disease
    • Ulcerative colitis
    • GERD
    • IBS
    • Others Applications
  • Europe Gastrointestinal Therapeutics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Reasons to subscribe to gastrointestinal therapeutics market databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of gastrointestinal therapeutics market databook

  • Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe gastrointestinal therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Europe Gastrointestinal Therapeutics Market, 2021-2033 (US$M)

No Access Stack Chart

Europe gastrointestinal therapeutics market statistics, by drug type, 2021-2033 (US$M)

No Access Pie Chart

Europe gastrointestinal therapeutics market statistics, by country, 2021-2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more